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Characterization of the Dog Lipocalin Allergen Can f 6 Sanny K. Chan, MD PhD, John W. Kappler, PhD, and Gina M. Clayton; National Jewish Health, Denver, CO. RATIONALE: Allergies to dogs are a critically important clinical problem that affect between 10%-30% of humans worldwide and continue to increase. Four of the seven currently named dog component allergens (Can f 1, Can f 2, Can f 4, and Can f 6) are lipocalins. Sensitization to Can f 6 is linked to the highest likelihood of allergic symptoms. Accurate biochemical and biophysical data for each is limited. METHODS: The cDNA encoding 6xHis-tagged Can f 6 was cloned, expressed in bacteria, and purified using a HisPur Ni-NTA Superflow Agarose nitrilotriacetic acid (NTA) column, followed by fast protein liquid chromatography (FPLC) size exclusion column, and then pooling fractions of the appropriate molecular weight. Initial crystallization trials were performed at room temperature by hanging drop vapor diffusion. Data were collected on a cryoprotected crystal on the 24-ID-C Synchrotron at the Advanced Photon Source at Argonne National Laboratory, processed, solved, and refined using Phaser and the CCP4 program suite. RESULTS: The purified recombinant Can f 6 protein has been crystalized. The resulting high-resolution x-ray diffraction data was used to solve the tertiary structure of the protein. This is the third dog lipocalin allergen whose structure has been characterized. CONCLUSIONS: This Can f 6 structure can now be used to identify potential sites of cross reactivity with other lipocalins and define allergenic epitopes that can be therapeutic targets. METHODS: Human IgE monoclonal antibodies (hIgE mAbs) against Der p 2 were identified by humanhybridoma technology using human B cells from mite allergic patients (5D10, 1B8, 2G1, 2F10). Their relative binding sites were compared by immunoassays with previously studied murine IgG (mIgG) mAb aDPX, 1D8, and 7A1. NMR analyses of Der p 2 alone and in complex with IgG and IgE antibodies were used to identify specific residues in the epitopes. RESULTS: Immunoassay results showed that the recognition of Der p 2 by three hIgE (5D10, 1B8, and 2G1) was inhibited by aDPX (less by 1D8), but the 2F10 bound to a different epitope than 1B8, 5D10, 2G1, aDpX, 1D8 and 7A1. NMR data confirmed that many similar residues of Der p 2 are influenced by the binding of aDPX, 5D10, 1B8, and 2G1, consistent with overlapping epitopes. NMR data identified different residues influenced by 1D8, 2F10, and 7A1 binding consistent with three functionally nonoverlapping epitopes. CONCLUSIONS: The combination of immunoassays to distinguish overlapping epitopes and NMR analyses to identify specific residues involved in Ab binding provided the first epitope mapping of hIgE mAbs to Der p 2. The mIgG and hIgE mAbs tested bound overlapping and/or nonoverlapping epitopes on Der p 2. The data will be valuable in the design of future therapies.
